Funding for this research was provided by:
Amyris, Inc., and ImmunityBio, Inc.
Received: 25 March 2022
Accepted: 6 October 2022
First Online: 2 November 2022
Change Date: 23 November 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41541-022-00578-7
: A.G., C.B.F., C.J.P., E.A.V., and P.S.S. declare no competing non-financial interests but the following competing financial interests. C.B.F. is co-inventor on patent applications relating to PCT/US2018/37783, “Nanostructured Lipid Carriers and stable emulsions and uses thereof.” A.G. and E.A.V. are co-inventors on U.S. patent application nos. PCT/US21/40388, “Co-lyophilized RNA and Nanostructured Lipid Carrier,” and 63/144,169, “A thermostable, flexible RNA vaccine delivery platform for pandemic response.” C.J.P. owns shares and possesses stock options in Amyris, Inc. P.S.S. owns shares of ImmunityBio, Inc. All other authors declare they have no competing interests.